This activity has expired. Credit is no longer available.
This activity is supported by educational grants provided by Amgen, AstraZeneca, Celgene Corporation, Incyte Corporation, Merck Sharp & Dohme Corp., Takeda Oncology, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Risk-Adapted Treatment of Indolent B-Cell Lymphomas: Application of Novel Agents

Amy Goodrich, MSN, CRNP
Johns Hopkins Kimmel Cancer Center

Dive into current strategies for managing patients with chronic lymphocytic leukemia and follicular lymphoma, including the risk-adapted treatment selection of new therapies based on factors such as patient age, performance status, and comorbidities. The latest data on the efficacy and safety of newly approved agents are presented, and strategies to treat common side effects reviewed.


Download Slides

These activities, certified for CME/CE/CPE credit, are jointly provided by

Annenberg Logo Harborside Press Logo

in collaboration with

Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.